Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer

NCT01229865 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

29

Enrollment

INDUSTRY

Sponsor class

Conditions

Differential Thyroid Cancer

Interventions

DRUG: VB-111

Sponsor

Vascular Biogenics Ltd. operating as VBL Therapeutics